Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
NovAccess Global Inc. (XSNX)
USD0.00
+0.00 (+0.00%)
US OTC Healthcare Biotechnology
Address
8834 Mayfield Road 44026
Chesterland, OH, US
Chesterland, OH, US
CEO
Dwain K. Morris-Irvin
Website
novaccessglobal.com
IPO
1998-09-21
CIK 1039466 ISIN US67001N1072
Description
Operating as a biopharmaceutical firm, NovAccess Global Inc. focuses on developing innovative immunotherapies to treat individuals with brain tumors across the United States. Their primary expertise is in pioneering research that leverages a patient's own immune system to target and eliminate cancerous cells. The company, founded in 1997, has its headquarters situated in Chesterland, Ohio.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.00
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
633
Beta
2.80
Float Shares
26.32M
Free Float %
42.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | -50.00% | +0.00% | +0.00% | -99.92% | -99.98% | -100.00% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.00
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-391.34
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-130.0% Q2'24: -470,008.7% (vs Q2'23)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q2'24: +56.3% (vs Q2'23)
-
Share dilution Biotechnology: -3.4%+26.0% Q2'24: -100.0% (vs Q2'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-2.13× Q2'24: -1.20× (vs Q2'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-314.8K
OE per share TTM
-10.89
Owner's Yield
-5,816.96%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
0.1%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
12
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Gemini Strategies LLC, Inc. | 47.75M | 6.80% | — | 47.75M | — | 47.75M | CO | Delaware | 2016-02-12 | ↗ |
| 2 | Gemini Master Fund, Ltd. | 41.31M | 2.90% | — | 41.31M | — | 41.31M | CO | Cayman Islands | 2018-02-14 | ↗ |
| 3 | Gemini Strategies, Inc. | 41.31M | 2.90% | — | 41.31M | — | 41.31M | CO | California | 2018-02-14 | ↗ |
| 4 | Steven Winters | 41.31M | 2.90% | — | 41.31M | — | 41.31M | IN | United States | 2018-02-14 | ↗ |
| 5 | David Sumner | 14.80M | 24.00% | — | 14.80M | — | 10.00 | IN | United Kingdom | 2024-06-11 | ↗ |
| 6 | Dawn Digital Limited | 14.80M | 24.00% | — | 14.80M | — | 10.00 | OO | British Virgin Islands | 2024-06-11 | ↗ |
| 7 | Innovest Global, Inc. | 7.50M | 82.40% | — | 7.50M | — | 10.00 | CO | Nevada | 2020-09-16 | ↗ |
| 8 | AJB Capital Investments, LLC | 1.95M | 7.74% | 1.95M | — | 1.95M | — | OO | United States | 2024-01-18 | ↗ |
| 9 | Dwain K. Morris-Irvin | 1.80M | 14.00% | 1.80M | — | 1.80M | 10.00 | IN | United States of America | 2021-04-16 | ↗ |
| 10 | Daniel G. Martin | 5.0K | 100.00% | — | 5.0K | — | 10.00 | IN | United States of America | 2020-06-10 | ↗ |
| 11 | TN3, LLC | 5.0K | 100.00% | — | 5.0K | — | 10.00 | OO | Wyoming | 2020-06-10 | ↗ |
| 12 | Company”) | 60.00 | 60.00% | 14.49M | — | 14.49M | 10.00 | IN | United States | 2013-07-02 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
3
Sells
0
Shares acquired
2.14M
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+2,142,857
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-05-31 | CASSARINI JOHN | Director | A-Award | A | Convertible loan* | 0 | 0.11 | — | 0 | — | ↗ |
| 2024-05-17 | Sumner David | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 14,700,000 | — | ↗ |
| 2023-03-13 | LAIRD NEIL J | Officer | A-Award | A | Stock Option (right to buy) | 428,571 | 0.18 | 75.0K | 428,571 | — | ↗ |
| 2023-03-13 | CASSARINI JOHN | Director | A-Award | A | Stock Option (right to buy) | 857,143 | 0.18 | 150.0K | 857,143 | — | ↗ |
| 2023-03-13 | Anderson Jason Michael | Director | A-Award | A | Stock Option (right to buy) | 857,143 | 0.18 | 150.0K | 857,143 | — | ↗ |
| 2022-03-18 | Anderson Jason Michael | Director | — | D | Common Stock, no par value | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-03-14 | Morris-Irvin Dwain | Officer | J-Other | A | Series B Preferred Stock, $0.01 par value | 600 | 0.00 | — | 600 | — | ↗ |
| 2022-03-14 | Martin Daniel G. | 10% Owner | J-Other | D | Series B Preferred Stock, $0.01 par value per share | 25,000 | 250,000.00 | 6.25B | 0 | — | ↗ |
| 2022-03-14 | CASSARINI JOHN | Director | — | D | Common Stock, no par value | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-01-20 | LAIRD NEIL J | Officer | P-Purchase | A | Common Stock, no par value | 250,000 | 0.20 | 50.0K | 260,000 | — | ↗ |
| 2021-10-03 | LAIRD NEIL J | Officer | A-Award | A | Common Stock, no par value | 10,000 | 0.00 | — | 10,000 | — | ↗ |
| 2021-09-10 | LAIRD NEIL J | Officer | — | D | Common Stock, no par value | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-01-19 | Yukich Larry Michael | Officer | A-Award | A | Common Stock, no par value | 200,000 | 0.00 | — | 200,000 | — | ↗ |
| 2020-11-23 | Morris-Irvin Dwain | Officer / 10% Owner | A-Award | A | Common Stock, no par value | 1,800,000 | 0.00 | — | 1,800,000 | — | ↗ |
| 2020-10-21 | Yukich Larry Michael | Officer | — | D | Common Stock, no par value | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-10-15 | Morris-Irvin Dwain | Officer | — | D | Common Stock, no par value | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-09-08 | Martin Daniel G. | Director / Officer / 10% Owner | J-Other | A | Common Stock, no par value | 7,500,000 | 0.00 | — | 7,500,000 | — | ↗ |
| 2020-09-08 | Innovest Global, Inc. | 10% Owner | — | D | Common Stock, no par value | 0 | 0.00 | — | 7,500,000 | — | ↗ |
| 2020-09-04 | Martin Daniel G. | Director / Officer / 10% Owner | J-Other | A | Series B Preferred Stock, $0.01 par value per share | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2020-06-02 | Martin Daniel G. | Director / Officer / 10% Owner | — | I | Series A Preferred Stock, $0.01 par value per share | 0 | 0.00 | — | 5,000 | — | ↗ |
| 2007-11-26 | RUSSAK MICHAEL A | Director | — | D | Stock Option | 500,000 | 0.36 | 180.0K | 0 | — | ↗ |
| 2007-11-12 | fundingsland osmund mark | Director | — | D | Stock Option | 500,000 | 0.36 | 180.0K | 0 | — | ↗ |
| 2007-10-23 | ANDERSON THOMAS A | Director | P-Purchase | A | Option | 1,500,000 | 0.36 | 540.0K | 1,500,000 | — | ↗ |
| 2007-08-28 | RUSSAK MICHAEL A | Director | — | D | Common Stock | 100,000 | 0.41 | 41.0K | 0 | — | ↗ |
| 2007-04-01 | Huitt Jeff J | Officer | — | D | Options | 500,000 | 0.46 | 230.0K | 0 | — | ↗ |
| 2006-07-20 | Grimes Joseph | Officer | — | D | Warrants | 112,000 | 1.69 | 189.3K | 0 | — | ↗ |
| 2006-04-30 | ALTOUNIAN BRIAN | Director | G-Gift | D | Common Stock | 350,000 | 0.10 | 35.0K | 3,650,000 | — | ↗ |
| 2006-04-27 | ALTOUNIAN BRIAN | Director | S-Sale | D | Common Stock | 474,000 | 1.79 | 846.1K | 2,326,000 | — | ↗ |
| 2006-04-17 | ALTOUNIAN BRIAN | Director | S-Sale | D | Common Stock | 500,000 | 2.03 | 1.02M | 2,800,000 | — | ↗ |
| 2006-04-05 | Grimes Joseph | Officer | — | D | Warrants | 500,000 | 0.51 | 255.0K | 0 | — | ↗ |
| 2006-01-31 | ALTOUNIAN BRIAN | Director | S-Sale | D | Common Stock | 300,000 | 1.35 | 405.0K | 3,300,000 | — | ↗ |
| 2004-12-21 | DJOKOVICH TOM M | Director / Officer / 10% Owner | G-Gift | D | Common Stock | 75,000 | 0.44 | 33.0K | 925,000 | — | ↗ |
| 2003-09-30 | DJOKOVICH THOMAS | Director / Officer | — | I | common stock | 0 | 0.00 | — | 16,978,000 | — | ↗ |
| 2003-09-30 | ALTOUNIAN BRIAN | Director / Officer | — | D | common stock | 0 | 0.00 | — | 4,000,000 | — | ↗ |
Executive team
Top executives
Shares Outstanding
61.65M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Dwain K. Morris-Irvin | Chief Executive Officer, Interim Principal Financial Officer & Director | 155.4K | — |
| Christopher Wheeler | President of Stemvax Therapeutics | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for XSNX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
